Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPD489 (Vyvanse) as adjunctive therapy in major depressive disorder
NCT01436149Phase 3Completed
- Sponsor
- Takeda
- Start
- Oct 2011
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Antidepressant + SPD489 with Antidepressant + Placebo (2 arms). Primary endpoint: Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale Total Score at 8 weeks. Started Oct 2011; status: completed.
02
Drugs
lisdexamfetamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01436149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01436149.